Erlotinib-induced acute interstitial lung disease associated with extreme elevation of the plasma concentration in an elderly non-small-cell lung cancer patient

Journal of Cancer Research and Therapeutics

Volumn 8, Issue 1, 2012, Pages 154-156

  Tsubata, Yukari ^a   Hamada, Akinobu ^b   Sutani, Akihisa ^a   Isobe, Takeshi ^a  

^a SHIMANE UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Elderly patient; epidermal growth factor receptor tyrosine kinase inhibitor; interstitial lung disease; non small cell lung cancer

Indexed keywords

CARBOPLATIN; DOCETAXEL; ERLOTINIB; MAGNESIUM OXIDE; METHYLPREDNISOLONE; PACLITAXEL; POLYCARBOPHIL CALCIUM; SIVELESTAT;

ACUTE DISEASE; ACUTE LUNG INJURY; AGED; ARTICLE; BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONVULSION; DISEASE COURSE; DRUG WITHDRAWAL; DYSPHAGIA; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG BIOPSY; LUNG NON SMALL CELL CANCER; MALE; NEUTROPENIA;

AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG DISEASES, INTERSTITIAL; LUNG NEOPLASMS; MALE; PROTEIN KINASE INHIBITORS; QUINAZOLINES;

EID: 84860451271     PISSN: 09731482     EISSN: 19984138     Source Type: Journal    
DOI: 10.4103/0973-1482.95201     Document Type: Article

References (11)

1. Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, et al. TRIBUTE Investigator Group. TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5892-9.
2. Shepherd FA, Rodringues PJ, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32. (Pubitemid 41058344)
3. Cohen MH, Johnson JR, Chen YF, Sridhara R, Pazdur R. FDA drug approval summary: Erlotinib (Tarceva) tablets. Oncologist 2005;10:461-6. (Pubitemid 41266326)
4. Hamada A, Sasaki J, Saeki S, Iwamoto N, Inaba S, Ushijima S, et al. Association of pharmacokinetics and germ-line mutations in EGFR and ABC transporters with erlotinib toxicity in patients with nonsmall cell lung cancer (NSCLC). J Clin Oncol 2009;27 Suppl:15s.
5. Lepper ER, Swain SM, Tan AR, Figg WD, Sparreboom A. Liquidchromatographic determination of erlotinib (OSI-774), an epidermal growth factor receptor tyrosine kinase inhibitor. J Chromatogr B Analyt Technol Biomed Life Sci 2003;796:181-8. (Pubitemid 38352722)
6. Inoue A, Saijo Y, Maemondo M, Gomi K, Tokue Y, Kimura Y, et al. Severe acute interstitial pneumonia and gefitinib. Lancet 2003;361:137-9. (Pubitemid 36092019)
7. Makris D, Scherpereel A, Copin MC, Colin G, Brun L, Lafitte JJ, et al. Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer. BMC Cancer 2007;7:150-3.
8. Ando M, Okamoto I, Yamamoto N, Takeda K, Tamura K, Seto T, et al. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2006;24:2549-56. (Pubitemid 46630633)
9. Takano T, Ohe Y, Kusumoto M, Tateishi U, Yamamoto S, Nokihara H, et al. Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib. Lung Cancer 2004;45:93-104. (Pubitemid 38757837)
10. Hidalgo M, Siu LL, Nemunaitis J, Rizzo J, Hammond LA, Takimoto C, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001;19:3267-79. (Pubitemid 32591445)
11. Yamamoto N, Horiike A, Fujisaka Y, Murakami H, Shimoyama T, Yamada Y, et al. Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors. Cancer Chemother Pharmacol 2008;61:489-96. (Pubitemid 350275984)